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Abstract
Background: Anaemia is frequently associated with both HIV-infection and HIV-related tuberculosis (TB) in antiretroviral
therapy (ART)-naïve patients in sub-Saharan Africa and is strongly associated with poor prognosis. However, the effect of
ART on the resolution of anaemia in patient cohorts with a high prevalence and incidence of tuberculosis is incompletely
defined and the impact of TB episodes on haemoglobin recovery has not previously been reported. We therefore
examined these issues using data from a well-characterised cohort of patients initiating ART in South Africa.
Methods: Prospectively collected clinical and haematological data were retrospectively analysed from patients
receiving ART in a South African township ART service. TB diagnoses and time-updated haemoglobin concentrations,
CD4 counts and HIV viral loads were recorded. Anaemia severity was classified according to WHO criteria. Multivariable
logistic regression analysis was used to determine factors independently associated with anaemia after 12 months
of ART.
Results: Of 1,140 patients with baseline haemoglobin levels, 814 were alive in care and had repeat values available
after 12 months of ART. The majority of patients were female (73%), the median CD4 count was 104 cells/uL and 30.5%
had a TB diagnosis in the first year of ART. At baseline, anaemia (any severity) was present in 574 (70.5%) patients and
was moderate/severe in 346 (42.5%). After 12 months of ART, 218 (26.8%) patients had anaemia of any severity and just
67 (8.2%) patients had moderate/severe anaemia. Independent predictors of anaemia after 12 months of ART included
greater severity of anaemia at baseline, time-updated erythrocyte microcytosis and receipt of an AZT-containing
regimen. In contrast, prevalent and/or incident TB, gender and baseline and time-updated CD4 cell count and
viral load measurements were not independent predictors.
Conclusions: Although anaemia was very common among ART-naive patients, the anaemia resolved during the
first year of ART in a large majority of patients regardless of TB status without routine use of additional interventions.
However, approximately one-quarter of patients remained anaemic after one year of ART and may require additional
investigations and/or interventions.
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Background
Anaemia is the most common haematological mani-
festation of HIV disease and is frequent among anti-
retroviral therapy (ART)-naïve patients in sub-Saharan
Africa, with a prevalence ranging from 45- 87% [1-5]. HIV-
related anaemia is associated with a decreased quality of
life [6-8], accelerated HIV disease progression [9,10], in-
creased risk of virological failure [11-13] and decreased
survival [9,14-17] .
The mechanisms contributing to HIV-related anaemia
are complex. HIV itself may result in an up-regulation
of cytokines and hepcidin causing anaemia through
inhibition of mucosal uptake of dietary iron and se-
questration of iron in bone marrow macrophages [18].
HIV may also cause dysregulated erythropoiesis through
direct viral infection of bone marrow progenitor cells,
although this remains controversial [19-23]. Tubercu-
losis (TB) is the commonest opportunistic infection
among HIV-infected patients in sub-Saharan Africa
and is likely an important cause of HIV-related an-
aemia, where anaemia occurs in up to 90% of patients
with HIV-associated TB [24-27]. Similar to HIV, TB
may also cause an anaemia of chronic disease through
upregulation of proinflammatory cytokines [28,29]. Add-
itionally, dissemination of TB to the gastro-intestinal
tract mucosa may result in iron deficiency anaemia
[30,31], while bone marrow involvement may cause
impairment of all hematopoietic cell lines [32-34]. In
sub-Saharan Africa additional factors may contribute
to anaemia in people living with HIV, including nutri-
tional deficiencies of iron, folate and vitamin B12 as
well as co-morbidities such as malaria, helminth in-
fections and opportunistic infections and also adverse
drug effects.
Large studies from industrialized countries appear to
indicate that antiretroviral therapy (ART) has strong
positive effects on haemoglobin recovery [35-39]. In sub-
Saharan Africa where the prevalence of HIV-related an-
aemia remains high, previous studies have shown that
ART is likely associated with significant haemoglobin re-
covery [1,2,40-46]. However, this is complicated by a lack
of an international consensus definition for anaemia,
which makes comparison of previous studies from this
region difficult. It is also unknown whether patients with
HIV-associated TB achieve similar haemoglobin recovery
as patients without TB. Therefore, we undertook a
retrospective cohort analysis to characterize changes in
haemoglobin concentration during the first year of ART
among patients in Cape Town with a high prevalence
and incidence of TB, define what proportion of patients
had resolution of baseline anaemia or maintained normal
haemoglobin levels after 12 months of ART and de-
termine risk factors independently associated with an-
aemia after 12 months of ART.
Methods
Study setting
The present study is part of on-going research at the
Hannan Crusaid Antiretroviral Centre in Gugulethu
township, Cape Town, South Africa which has previ-
ously been described in detail [47,48]. Patients consecu-
tively enrolled in the ART programme were eligible for
the study if they were ART naïve, at least 16 years of
age, and subsequently initiated ART. All patients pro-
vided written informed consent and the study was ap-
proved by the human ethics committee of the University
of Cape Town, Cape Town, South Africa.
Patients were enrolled between September 2002 and
May 2006 (a time period for which very complete clin-
ical records and time-updated TB, CD4 count and viral
load data were available) and were eligible to start ART
if they had either a World Health Organization (WHO)
stage 4 disease or CD4 count <200 cells/uL in accord-
ance with national ART guidelines at that time. First-line
ART regimens were comprised of two nucleoside reverse
transcriptase inhibitors, which included either stavudine
(d4T) or zidovudine (AZT) with lamivudine (3TC) and
a non-nucleoside reverse transcriptase inhibitor (pre-
dominantly efavirenz (EFV)). All patients received daily
trimethoprim-sulphamethoxazole prophylaxis. At the time,
national ART guidelines gave no recommendations for the
management of HIV-related anaemia and therefore no in-
terventions for anaemia were routinely implemented.
Patients were referred for ART initiation from pri-
mary care clinics, TB clinics and antenatal clinics and
received routine clinical review at a screening visit,
ART initiation, after 4, 8 and 16 weeks of ART, and
thereafter at least every 4 months. Haemoglobin concen-
trations as well as mean corpuscular volumes (MCV),
blood CD4 cell counts and plasma HIV viral load levels
were done prior to ART initiation and at least every
4 months thereafter.
TB screening and diagnosis
Several different investigations were available for the
diagnosis of TB either prior to ART initiation or during
ART follow-up and included: sputum smear fluores-
cence microscopy, automated liquid culture of sputum
using mycobacterial growth indicator tubes (MGIT 960,
Becton Dickinson, Sparks, Maryland, USA), chest radi-
ology, ultrasonography and fine needle lymph node aspir-
ation (FNA) cytology. Culture-positive specimens were
speciated using polymerase chain reaction (PCR). A large
majority of TB cases were culture-proven, however any
culture-negative TB diagnosis was defined by strong clin-
ical or histological evidence of active TB, radiological ab-
normalities consistent with active TB and the clinician’s
decision to treat with a full course of anti-TB therapy. Pa-
tients diagnosed with TB were given a rifampicin-based
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anti-tuberculosis regimen as part of a direct observed treat-
ment short-course (DOTS) strategy.
Definitions
Anaemia severity was classified according to WHO criteria
[49]: no anaemia (haemoglobin concentration ≥13.0 g/dL
for males, ≥12.0 g/dL for females), mild anaemia (11.0-
12.9 g/dL for males, 11.0-11.9 g/dL for females), moderate
anaemia (8.0-10.9 g/dL for males and females) or severe
anaemia (<8.0 g/dL for males and females). Patients with-
out anaemia at the time of ART initiation but who had an-
aemia (of any severity) after 12 months of ART were
defined as having ‘incident anaemia’. ‘Persistent anaemia’
was defined as the presence of anaemia (of any severity)
both prior to ART initiation and after 12 months of ART.
A ‘baseline haemoglobin’ was defined as a haemoglobin
concentration within 90 days of ART initiation for those
without a known TB diagnosis prior to ART initiation (no
prevalent TB), and within 30 days for those with prevalent
TB, as anti-TB therapy is known to be associated with
rapid changes in haemoglobin concentration [50-52].
Patients who had previously been diagnosed with TB
and completed anti-TB treatment prior to enrolment in
the ART cohort defined those with a ‘past history of TB’.
‘Referred TB’ was defined as those with a known TB
diagnosis who were referred from TB clinics to the ART
service for initiation of ART and who were currently tak-
ing TB treatment at the time of starting ART. Any new
clinical episode of TB that was diagnosed in the ART
service around the time of ART initiation or at any point
within the first year of starting ART was defined as “TB
in the first year of ART”.
Data analysis
Data were analysed using Stata version 12.0 (College
Station, Texas, USA). The main analysis was restricted to
those who had haemoglobin results available at the time of
ART initiation and also at 12 months after ART initiation.
Time-updated intervals were defined by laboratory mea-
surements at ART initiation (baseline) and at 4, 8 and
12 months of ART. Chi-squared tests, Wilcoxin rank-sum,
Kruskal-Wallis tests and t-tests were used when appropri-
ate. Multivariable logistic regression analysis was used to
determine factors independently associated with anaemia
(any severity) after 12 months of ART; a priori risk factors
(gender and AZT-exposure) and variables meeting the pre-
defined cutoff of P ≤ 0.1 in the univariable model were in-
cluded in the multivariable model. Sensitivity analyses were
undertaken to determine if haemoglobin recovery was af-
fected by the exclusion of patients who died or were lost-
to-follow-up in the first year of ART, where it was assumed
that such patients had no haemoglobin recovery while re-
ceiving ART (median improvement of zero). All statistical
tests were two-sided at a value of 0.05.
Results
Baseline patient characteristics
Of 1,544 patients meeting study inclusion criteria, 1140
had baseline haemoglobin levels available. Haemoglobin
levels after 12 months of ART were not available for 326
patients due to death, loss to follow-up, transfer-out or
repeat testing not being done and they were therefore
excluded (Figure 1). The remaining 814 patients were in-
cluded in the main analysis (Figure 1).
Patients were predominantly female and had a median
age of 33 years (IQR, 29–39). They also tended to have
advanced HIV disease, with a median CD4 count of
104 cells/μL (IQR, 50–156) and a median viral load of
4.8 log copies/mL (IQR, 4.4-5.2) (Table 1). There were
168 patients (20.6%) who received AZT at any point
during the first year of ART, of whom 59 (7.2%) re-
ceived an AZT-containing regimen continuously, 22 (2.7%)
switched AZT to another drug and 87 (10.7%) switched
another drug to AZT. Among the 22 patients who switched
from an AZT-containing regimen, severe anaemia was cited
as the reason for the drug switch in only 2 patients.
The baseline characteristics of patients known to be
alive at 12 months but for whom 12 month haemoglobin
level results were missing (n = 173) or who transferred
out (n = 26) in the first year of the ART programme
were similar to those included in the final analysis (data
not shown). However, those who died (n = 83) or were
lost-to-follow up (n = 44) in the first year of ART were
more likely to be male, have more advanced immuno-
suppression and have a TB diagnosis within the first year
of ART compared to those included in the final analysis
(data not shown). Among patients who died in the first
year of ART, 54 (65.1%) had moderate or severe anaemia
at baseline and 52 (62.7%) had moderate or severe an-
aemia at the last available measurement before death.
Of 62 patients who died in the first 4 months of ART,
40 (64.2%) had moderate or severe anaemia prior to
ART initiation.
Prevalence of anaemia
At the time of ART initiation, 574 patients (prevalence
70.5%, 95% CI 67.3-73.6) had anaemia, which was classi-
fied as mild, moderate, or severe in 228 (28.0%), 310
(38.1%) and 36 (4.4%) patients, respectively. Anaemia
was more severe in patients who were younger, female,
had lower CD4 cell counts, higher HIV viral loads and
had no medical history of TB (Table 1).
TB diagnoses
At ART initiation, 131 (16.1%) patients were receiving
anti-TB therapy and 117 (14.4%) had new TB disease di-
agnosed within the first year of ART (Table 1). There-
fore, 248 (30.5%) patients were receiving treatment for
TB at some time-point during the first year of ART.
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Time-updated anaemia severity during the first year
of ART
With increasing duration of ART, the prevalence and se-
verity of anaemia decreased (Figure 2). After 12 months
of ART, 596 (73.2%) patients had normal haemoglo-
bin levels, whereas 218 patients (26.8%) had anaemia,
of which 67 patients (8.2%) had either moderate or se-
vere anaemia. The overall prevalence of anaemia after
12 months of ART decreased by 62.0%, including an
80.6% decrease in moderate or severe anaemia. Of 199
patients who either transferred out or who were alive
and in care but did not have haemoglobin measure-
ments at 12 months, the severity and prevalence of an-
aemia at 4 and 8 months after ART initiation were similar
to those included in the final analysis (p = 0.246 and
p = 0.499, respectively).
Persistent and incident anaemia after 12 months of ART
Among those with anaemia at the time of ART initiation
(n = 574), 379 (66.0%) had normal haemoglobin levels
after 12 months of ART. Of 195 (34.0%) patients with
persistent anaemia after 12 months of ART, 62 (10.8%)
had moderate/severe anaemia. Of 240 patients without
anaemia at the time of ART initiation, 23 patients (9.6%)
developed incident anaemia of which 5 (2.1%) were moder-
ate or severe.
Changes in haemoglobin during the first year of ART
During the first year of ART, the median haemoglobin
level among all patients (n = 814) improved from 11.3 g/dL
to 12.9 g/dL, representing a median improvement of
1.6 g/dL (p < 0.001). Significant improvements in haemo-
globin levels and corresponding resolution of anaemia was
observed during the first year of ART, irrespective of TB
disease status, gender, AZT exposure, baseline anaemia
severity, baseline CD4 count or baseline HIV viral load
(Table 2 and Figure 3). While the greatest haemoglobin re-
covery was among those with moderate or severe anaemia
at ART initiation, such patients were also much more
likely to remain anaemic after 12 months of ART (Table 2
and Figure 3A). Despite significant increases in haemoglo-
bin levels from baseline, females (Figure 3B) and those
Figure 1 Flow diagram showing the number of patients included in the analysis and the prevalence of anaemia.
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who had received an AZT-containing regimen (Figure 3C)
were more likely to have anaemia 12 months after starting
ART. Of note, the proportion of patients with anaemia
and the median haemoglobin level improvement after
12 months of ART did not differ among those who had
TB during the first year of ART compared to those who
did not (p = 0.079 and p = 0.198, respectively) (Figure 3D).
In a sensitivity analysis that included patients who
died or were lost to follow-up during the first year
of ART (n = 941) and who were assumed to have no
haemoglobin improvement, the median improvement in
haemoglobin levels after one year were slightly decreased
(median overall improvement 1.3 g/dL, p < 0.001). How-
ever, overall and among all patient sub-groups, there was
no difference in the improvement of haemoglobin levels
(data not shown).
Risk factors for anaemia after one year of ART
We undertook logistic regression analyses to determine
factors independently associated with anaemia (any se-
verity) after 12 months of ART. In univariable analysis,
several risk factors met the pre-defined criteria for in-
clusion in the multivariable model, but notably TB in
the first year of ART and CD4 cell count (baseline or
time-updated) did not demonstrate associations with
anaemia after 12 months of ART (Table 3). In the multi-
variable model, risk factors included greater severity of
baseline anaemia, lower time-updated MCV and AZT
Table 1 Baseline patient characteristics (n = 814)
WHO anaemia severity classification at ART initiation
All
(n = 814)
None
(29.5%; n = 240)
Mild
(28.0%; n = 228)
Moderate
(38.1%; n = 310)
Severe
(4.4%; n = 36)
P-value
Age (at baseline), median (IQR) 33 (29–39) 34 (29–40) 33 (29–40) 32 (28–37) 31 (27–37) 0.008
Gender
Male 224 (27.5) 102 (42.5) 87 (38.2) 30 (9.7) 5 (13.9) <0.001
Female 590 (72.5) 138 (57.5) 141 (61.8) 280 (90.3) 31 (86.1)
WHO disease stage (at baseline)
1 or 2 185 (22.7) 56 (23.3) 55 (24.1) 69 (22.3) 5 (13.9) 0.584
3 or 4 629 (77.3) 184 (76.7) 173 (75.9) 241 (77.7) 31 (86.1)
Previous history of TB treatment
No 422 (51.8) 109 (45.4) 126 (55.3) 162 (52.3) 15 (69.4) 0.023
Yes 392 (48.2) 131 (54.6) 102 (44.7) 148 (47.7) 11 (30.6)
ART regimen
AZT-free throughout 646 (79.4) 207 (86.3) 187 (82.0) 221 (71.3) 31 (86.1) <0.001
Any AZT exposure 168 (20.6) 33 (13.8) 41 (18.0) 89 (28.7) 5 (13.9)
CD4 cell count (cells/μL)aa
Median, IQR 104 (50–156) 113 (56–164) 117 (63–169) 93 (44–146) 85 (31–125) 0.002
<100 383 (47.2) 109 (45.6) 90 (39.7) 164 (53.1) 20 (55.6) 0.013
≥100 428 (52.8) 130 (54.4) 137 (60.4) 145 (46.9) 16 (44.4)
HIV viral load (log copies/mL),
median (IQR)b
4.8 (4.4-5.2) 4.8 (4.3-5.1) 4.8 (4.4-5.2) 4.9 (4.5-5.3) 5.0 (4.7-5.3) 0.002
MCV (fL)c
Median, IQR 90 (86–95) 92 (88–96) 90 (87–94) 89 (84–94) 83 (75–95) <0.001
<80 56 (7.0) 5 (2.1) 9 (4.0) 28 (9.2) 14 (38.9) <0.001
80-100 671 (83.7) 205 (87.0) 200 (88.5) 250 (82.2) 16 (44.4)
>100 75 (9.4) 26 (11.0) 17 (7.5) 26 (8.6) 6 (16.7)
TB disease status
TB free in first year of ART 566 (69.5) 180 (75.0) 160 (70.2) 204 (65.8) 22 (61.1) 0.148
Referred TB 131 (16.1) 34 (14.2) 38 (16.7) 54 (17.4) 5 (13.9)
TB in first year of ART 117 (14.4) 26 (10.8) 30 (13.2) 52 (16.8) 9 (25.0)
a3 missing CD4 cell count results, b5 missing HIV viral load results, c12 missing MCV results.
Abbreviations: ART; antiretroviral therapy; AZT; zidovudine; IQR, interquartile range; MCV, mean corpuscular volume; TB, tuberculosis; WHO, World Health
Organization. All values are proportions (%) unless otherwise stated.
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exposure. Additional multivariable analyses demon-
strated that the independent risk factors for both incident
and persistent anaemia were identical to those identified
among all patients, with the exception that baseline an-
aemia severity was not associated with incident anaemia.
Discussion
Although anaemia was very common among patients
starting ART in this South African cohort, this resolved
in approximately two-thirds of patients during the first
12 months of ART. Significant haemoglobin recovery
occurred regardless of prevalent and/or incident TB,
gender, AZT exposure, baseline anaemia severity, CD4
cell count and HIV viral load measurements. These results
suggest that ART is strongly associated with the resolution
of HIV-related anaemia in the majority of patients without
routine use of additional specific interventions.
More than 70% of patients initiating ART in our study
had anaemia, consistent with other studies from sub-
Saharan Africa [1-5]. While the prevalence of HIV-
related anaemia will inevitably vary between settings,
comparative studies have been made difficult by the use
of non-standardized definitions for anaemia. Despite a
WHO definition for anaemia that was proposed more
than 45 years ago [53], several studies of HIV-related an-
aemia have used non-standardized definitions including
simple haemoglobin concentration cut-offs for all pa-
tients that don’t take into account gender differences
[1,11,40-42,46,54]. This may bias results towards lower
prevalence estimates and underestimate the scope of the
problem. Future research of HIV-related anaemia should
use standardized definitions, such as the WHO proposed
definition [49] to improve comparability of studies.
Receipt of ART for 12 months was associated with a
62% decrease in the overall prevalence of anaemia and
a resolution of anaemia in 66% of patients with anaemia
at ART initiation. Significant haemoglobin recovery
was observed among all patients, including sub-groups
stratified by risk factors for anaemia. Our findings are
in agreement with several other studies from both low-
and high-resource settings that demonstrate a strong,
consistent benefit of ART for HIV-related anaemia
[1,14,17,35,37-39,41,44,45,54,55]. Importantly, less than
10% of patients receiving ART for 12 months devel-
oped new anaemia and this was predominantly mild
in severity. For patients in whom anaemia is not life
threatening and a blood transfusion is not required,
these data suggest that use of ART alone is likely to
result in the resolution of anaemia in the majority of
patients.
Improvements in haemoglobin concentration did not
differ between patients with prevalent and/or incident TB
and those of patients who remained ‘TB-free’ throughout
the first year of ART. TB is strongly associated with HIV-
related anaemia in several settings [24-27]. This likely
reflects the fact that both TB and HIV infection may con-
tribute to downstream anaemia by acting upon a common
pathway through the up-regulation of pro-inflammatory
cytokines, especially IL-6, and a subsequent increase in
hepcidin, which inhibits mucosal absorption of iron and
Figure 2 Time-updated changes in the prevalence and severity of anaemia amongst patients during the first year of ART
receipt. Anaemia was classified according to WHO criteria. At 0, 4, 8 and 12 months of ART there were 814, 674, 714 and 814
observations, respectively.
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favours sequestration of iron in bone marrow macro-
phages [18]. This results in inadequate iron availability for
on-going erythropoiesis and eventually anaemia. The
present study indicates that recovery of haemoglobin
levels can be expected in patients with HIV-associated
TB who receive ART for 12 months in combination with
TB treatment for 6 months or more. Haemoglobin recov-
ery in such patients is thus likely achieved through de-
creased immune activation.
Haemoglobin recovery among those exposed to an
AZT-containing regimen was similar to those without
exposure to AZT, consistent with other African-based
studies [41,45,46,55]. According to the 2013 WHO con-
solidated ART guidelines [56], AZT is recommended as
part of alternative first line regimens for those in whom
tenofovir/lamivudine/efavirenz is either contradicted or
not available, and also as part of second line treatment.
Reassuringly, when AZT is used or required, it appears
that most African patients can be expected to neverthe-
less have significant recovery of haemoglobin concentra-
tions. However, as AZT was an independent risk factor
for anaemia after 12 months of ART [1,37,38,42] a drug
switch in those receiving AZT who remain anaemic dur-
ing ART may nevertheless be required in a proportion
of patients.
CD4 cell count and HIV viral load (either baseline or
time-updated) were not independently associated with
anaemia after 12 months of ART. Additionally, greater
improvements in haemoglobin concentration were noted
among those with very high baseline viral loads, consist-
ent with other studies which have found large haemoglo-
bin improvements among those with high viral load
or advanced immunosuppression at baseline [37,42] or
among those achieving HIV viral suppression [55]. These
data support the hypothesis that through a reduction in
HIV viraemia and/or improvement of opportunistic in-
fections and a subsequent decrease in immune activa-
tion, ART helps resolve anaemia of chronic disease [57].
Therefore, anaemia persisting after several months or
years of ART may not be related to HIV disease, but due
to other underlying causes.
Microcytosis (MCV < 80 fL) was uncommon, yet was
a very strong independent predictor of anaemia after
12 months of ART, similar to previous studies [1,2,38,41].
Microcytosis is suggestive of, but not diagnostic for, abso-
lute iron deficiency and may also be caused by thalassae-
mia or anaemia of chronic disease, either with or without
absolute iron deficiency [58-60]. Patients with iron-
deficiency would not be expected to have resolution of
anaemia with ART alone without increased dietary iron
intake. Iron studies and additional inflammatory bio-
markers were not available and we were therefore unable
to further investigate the mechanisms that underpin
HIV-related anaemia before and during ART. While ART
with or without anti-TB treatment may result in a reduc-
tion of cytokine-associated cachexia [61] with resultant
improved nutritional status, iron studies may be war-
ranted in patients with moderate or severe anaemia prior
to ART initiation or in those who remain anaemic des-
pite ART, in order to identify patients that may benefit
from iron supplementation.
While nearly three-quarters of patients had normal
haemoglobin levels after receipt of ART for 12 months,
an important minority (27%) remained anaemic. Al-
though only 8% of all patients had moderate or severe
anaemia after 12 months ART, even mild anaemia can
be associated with decreased quality of life and increased
mortality risk [6-9,17,62]. Because HIV-related anaemia
Table 2 Median haemoglobin improvement stratified by
risk factors for anaemia (n = 814)
Overall median change
in Hb from baseline to
12 months ART
P-value* P-value**
Overall +1.6 - <0.001
Gender
Male (n = 224) +1.3 <0.001 <0.001
Female (n = 590) +1.7 <0.001
ART regimen
AZT-free throughout
(n = 646)
+1.5 0.480 <0.001
Any AZT exposure
(n = 168)
+1.7 <0.001
Baseline anaemia
severity
None (n = 240) +0.4 <0.001 0.896
Mild (n = 228) +1.5 <0.001
Moderate (n = 310) +2.6 <0.001
Severe (n = 36) +5.1 <0.001
CD4 cell count
(cells/μL)
<100 (n = 383) +1.7 0.052 <0.001
≥100 (n = 428) +1.4 <0.001
Baseline HIV viral load
(log copies/mL)
<5.00 (n = 498) +1.4 <0.001 <0.001
5.00-5.49 (n = 211) +1.8 <0.001
>5.50 (n = 100) +2.1 <0.001
TB disease status
TB free (n = 566) +1.5 0.198 <0.001
Referred TB (n = 131) +1.6 <0.001
TB in first year of ART
(n = 117)
+1.7 <0.001
*P-value for difference in overall median haemoglobin change from baseline
to 12 months after starting ART.
**P-value for difference between median haemoglobin level at baseline and
median haemoglobin level after 12 months of ART.
Abbreviations: ART, antiretroviral therapy; TB, tuberculosis.
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is complex and likely multifactorial is not surprising
that some patients may require multiple interventions.
Therefore, elucidating additional causes of anaemia for
those with persistent anaemia during ART is important
for determining which interventions are appropriate and
when they should be considered during ART. Given that
those who had moderate or severe anaemia at ART initi-
ation were more likely to have persistent anaemia during
ART and also constituted two-thirds of those who died
during the first year of ART, such patients should be
prioritized for additional investigations +/− adjunctive
interventions either when initiating ART, or very early
during ART. Interventions may include routine microbio-
logical investigation for TB [24], nutritional supplements,
additional laboratory investigation for and treatment of
concomitant diseases and opportunistic infections, changes
A D
B E
C F
Figure 3 Time-updated changes in the prevalence of anaemia (any severity) among patients receiving ART stratified by known or possible
risk factors for anaemia A) baseline anaemia severity (classified according to WHO criteria) B) gender C) AZT exposure during first year of ART
D) TB-disease status E) baseline CD4 cell count F) baseline HIV viral load. *P < 0.05 for the difference in the proportion of patients with anaemia
across each group at the given time interval using chi-squared test. †P < 0.05 for the difference in the proportion of patients with anaemia at baseline and
those with anaemia after 12 months of ART for each individual variable using chi-squared test. Abbreviations: AZT, zidovudine; TB, tuberculosis.
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Table 3 Risk factors for anaemia after 12 months of ART use (n = 814)
Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Baseline characteristics
Age (years)
<35 1.00 0.166
≥35 1.01 (1.00-1.02)
Gender
Male 1.00 0.002 1.00 0.805
Female 1.78 (1.22-2.59) 1.06 (0.68-1.66)
WHO disease category
1/2 1.00
3/4 1.02 (0.94-1.11)
CD4 category (cells/μL)
≥100 1.00 0.576
<100 1.09 (0.80-1.49)
HIV viral load (log copies/mL)
<5.0 1.00 0.812
5.0-5.49 1.07 (0.75-1.54)
≥5.5 1.16 (0.72-1.86)
WHO anaemia severity
none 1.00 <0.001 1.00 <0.001
Mild 3.29 (1.95-5.55) 3.76 (2.14-6.62)
Moderate 5.56 (3.42-9.06) 5.44 (3.14-9.40)
severe 13.21 (6.00-29.10) 10.69 (4.52-25.28)
MCV (fL)
>100 1.00 0.093
80-100 1.10 (0.63-1.92)
<80 2.05 (0.96-4.35)
Time-updated characteristics
AZT exposure in first year of ART
AZT-free throughout 1.00 <0.001 1.00 0.009
Any AZT exposure 1.90 (1.32-2.73) 1.74 (1.15-2.62)
CD4 category (cells/μL)
≥100 1.00 0.349
<100 1.44 (0.68-3.01)
HIV viral load (copies/mL)
<1000 1.00 0.064 1.00 0.676
≥1000 1.91 (0.98-3.74) 1.18 (0.54-2.55)
MCV (fL)
>100 1.00 <0.001 1.00 <0.001
80-100 3.65 (2.50-5.32) 3.39 (2.23-5.17)
<80 13.13 (2.70-63.93) 12.60 (2.12-74.80)
TB disease status
TB free in first year of ART 1.00 0.441
Referred TB at ART initiation 0.95 (0.61-1.47)
TB in first year of ART 1.31 (0.95-2.01)
Abbreviations: AZT; zidovudine; MCV, mean corpuscular volume; TB, tuberculosis; WHO, World Health Organization.
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to medications known to be associated with anaemia
(including trimethoprim-sulphamethoxazole and AZT) and
should include more frequent patient follow-up to deter-
mine when a patient may require hospitalisation [58].
Study strengths include that this was an analysis of pro-
spectively collected data from a large well-characterized
cohort. This study expands previous knowledge by report-
ing haemoglobin recovery at multiple time points during
the first year of ART, using a standardised definition for
anaemia, and being undertaken in a very high TB inci-
dence setting. While anaemia interventions were not im-
plemented routinely, data was not available regarding
treatment of anaemia for patients and this may have con-
tributed to haemoglobin recovery in some individuals.
Pregnancy status was not available during ART follow-up,
which may have slightly overestimated the prevalence of
baseline anaemia, contributed to incident or persistent an-
aemia during ART and some pregnancy-related anaemia
may have otherwise resolved without ART. However, in
previous studies conducted at the same study clinic, the
proportion of females initiating ART who were pregnant
was small and ranged from 4 to 14% [63,64]. Data regard-
ing contributing factors to anaemia such as toxicity from
trimethoprim-sulphamethoxazole, acute blood loss, other
opportunistic infections and nutritional deficiencies, as
well as attributable causes of death, were not available and
thus could not be further investigated. However, this study
was done under routine programme conditions, which
improves generalizability of findings. By including only
patients with haemoglobin results available at ART and
12 months, haemoglobin recovery associated with ART
may have been overestimated by excluding some patients
who died or lost-to-follow-up and would be expected to
have poor haemoglobin recovery. However, sensitivity ana-
lyses including such patients still demonstrated strong evi-
dence of haemoglobin recovery both overall and within
each sub-group of patients. Additionally, patients known
to be alive, but without 12-month haemoglobin results
available, had similar baseline characteristics and haemo-
globin recovery compared to those included in the final
analysis suggesting that their exclusion likely did not affect
the findings.
Conclusion
In conclusion, despite very advanced immunodeficiency
and a high prevalence of anaemia at ART initiation,
approximately three-quarters of patients had normal
haemoglobin levels after 12 months of ART, including
two-thirds of patients with baseline anaemia. ART was
associated with significant haemoglobin recovery irre-
spective of gender, ART regimen, prevalent and/or inci-
dent TB or CD4 cell count. A large majority of patients
receiving ART will have resolution of anaemia without
additional specific interventions and therefore, ART should
be considered the primary intervention for HIV-related an-
aemia in sub-Saharan Africa. However, for the one-quarter
of patients who do not achieve normalization of haemoglo-
bin levels during the first year of ART, additional investiga-
tions +/− interventions may be required.
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